Quinoxaline Moiety: A Potential Scaffold against Mycobacterium tuberculosis

被引:28
|
作者
Montana, Marc [1 ,2 ]
Montero, Vincent [1 ]
Khoumeri, Omar [1 ]
Vanelle, Patrice [1 ,3 ]
机构
[1] Aix Marseille Univ, CNRS, ICR, Equipe Pharmacochim Radicalaire,Fac Pharm, F-13005 Marseille, France
[2] Oncopharma, AP HM, F-13015 Marseille, France
[3] AP HM, Serv Cent Qualite & Informat Pharmaceut SCQIP, F-13005 Marseille, France
来源
MOLECULES | 2021年 / 26卷 / 16期
关键词
quinoxaline; Mycobacterium; tuberculosis; SAR; biological applications; chemistry; IN-VITRO; ANTIMYCOBACTERIAL ACTIVITY; 1,4-DI-N-OXIDE DERIVATIVES; AMIDE DERIVATIVES; DESIGN; 1,2-DIAMINES; RESISTANT; DISCOVERY; 3D-QSAR; GREEN;
D O I
10.3390/molecules26164742
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background. The past decades have seen numerous efforts to develop new antitubercular agents. Currently, the available regimens are lengthy, only partially effective, and associated with high rates of adverse events. The challenge is therefore to develop new agents with faster and more efficient action. The versatile quinoxaline ring possesses a broad spectrum of pharmacological activities, ensuring considerable attention to it in the field of medicinal chemistry. Objectives. In continuation of our program on the pharmacological activity of quinoxaline derivatives, this review focuses on potential antimycobacterial activity of recent quinoxaline derivatives and discusses their structure-activity relationship for designing new analogs with improved activity. Methods. The review compiles recent studies published between January 2011 and April 2021. Results. The final total of 23 studies were examined. Conclusions. Data from studies of quinoxaline and quinoxaline 1,4-di-N-oxide derivatives highlight that specific derivatives show encouraging perspectives in the treatment of Mycobacterium tuberculosis and the recent growing interest for these scaffolds. These interesting results warrant further investigation, which may allow identification of novel antitubercular candidates based on this scaffold.
引用
收藏
页数:23
相关论文
共 50 条
  • [21] β-Aminopropioamidoximes derivatives as potential antitubercular agents against anthropozoonotic infections caused by Mycobacterium tuberculosis and Mycobacterium bovis
    Kayukova, Lyudmila
    Bismilda, Venera
    Turgenbayev, Kairat
    Uzakova, Asem
    Baitursynova, Gulnur
    Jussipbekov, Umirzak
    Mukanova, Meruyert
    Chingissova, Lyailya
    Dyussembayeva, Gulnur
    Borsynbayeva, Assiya
    Yerlanuly, Azamat
    Auyezov, Ablay
    VETERINARY WORLD, 2025, 18 (03) : 731 - 745
  • [22] Identification of peptidomimetic compounds as potential inhibitors against MurA enzyme of Mycobacterium tuberculosis
    Kumar, Prateek
    Saumya, Kumar Udit
    Giri, Rajanish
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2020, 38 (17): : 4997 - 5013
  • [23] Potential of Casiopeinas® Copper Complexes and Antituberculosis Drug Combination against Mycobacterium tuberculosis
    Barbosa, A. R.
    Caleffi-Ferracioli, K. R.
    Leite, C. Q. F.
    Garcia-Ramos, J. C.
    Toledano-Magana, Y.
    Ruiz-Azuara, L.
    Siqueira, V. L. D.
    Pavan, F. R.
    Cardoso, R. F.
    CHEMOTHERAPY, 2015, 61 (05) : 249 - 255
  • [24] Is the efflux pump inhibitor Verapamil a potential booster for isoniazid against Mycobacterium tuberculosis?
    Ribeiro do Amaral, Renata Claro
    Caleffi-Ferracioli, Katiany Rizzieri
    Demitto, Fernanda de Oliveira
    de Almeida, Aryadne Larissa
    Dias Siqueira, Vera Lucia
    de Lima Scodro, Regiane Bertin
    Fujimura Leite, Clarice Queico
    Pavan, Fernando Rogerio
    Cardoso, Rosilene Fressatti
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 56 : 1 - 7
  • [25] THE POTENTIAL EFFECT OF EZETIMIBE AGAINST MYCOBACTERIUM TUBERCULOSIS INFECTION IN TYPE II DIABETES
    Kuo, C. P.
    Tsai, I. F.
    Lu, Y. T.
    RESPIROLOGY, 2016, 21 : 92 - 92
  • [26] Ruthenium(II) complexes with hydroxypyridinecarboxylates: Screening potential metallodrugs against Mycobacterium tuberculosis
    Barbosa, Marilia I. F.
    Correa, Rodrigo S.
    Pozzi, Lucas V.
    Lopes, Erica de O.
    Pavan, Fernando R.
    Leite, Clarice Q. F.
    Ellena, Javier
    Machado, Sergio de P.
    Von Poelhsitz, Gustavo
    Batista, Alzir A.
    POLYHEDRON, 2015, 85 : 376 - 382
  • [27] Potential effect of ezetimibe against Mycobacterium tuberculosis infection in type II diabetes
    Tsai, I-Fang
    Kuo, Chiu-Ping
    Lin, Andrew B.
    Chien, Ming-Nan
    Ho, Hsin-Tsung
    Wei, Tsai-Yin
    Wu, Chien-Liang
    Lu, Yen-Ta
    RESPIROLOGY, 2017, 22 (03) : 559 - 566
  • [28] Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis
    Srivastava, Shashikant
    Cirrincione, Kayle N.
    Deshpande, Devyani
    Gumbo, Tawanda
    FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [29] Identification of potential Mycobacterium tuberculosis topoisomerase I inhibitors: A study against active, dormant and resistant tuberculosis
    Sridevi, Jonnalagadda Padma
    Suryadevara, Priyanka
    Janupally, Renuka
    Sridhar, Jogula
    Soni, Vijay
    Anantaraju, Hasitha Shilpa
    Yogeeswari, Perumal
    Sriram, Dharmarajan
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 72 : 81 - 92
  • [30] Active drugs against Mycobacterium tuberculosis
    Coll, Pere
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2009, 27 (08): : 474 - 480